Oral allergenspecific immunotherapy and the way of its improvement



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Oral method of allergen-specific immunotherapy (ASIT) is found to be the safe and available for the patients with allergic diseases. In this review the mechanisms of oral tolerance formation and the results of the efficacy and safety of oral ASIT are presented. The modern dosage forms of oral allergovaccines are analyzed.

About the authors

L R Vykhrystsenkо

Vitebsk Medical University

Email: all-vgmu@mail.ru
Vitebsk Medical University

References

  1. Jutel M., Akdis M., Blaser K., Akdis C.A. Mechanisms of allergen specific immunotherapy - T-cell tolerance and more. Allergy. 2006, v. 61, р. 796-807.
  2. Bagnasco M., Morbelli S., AtrinettiV. et al. Allergen biodistribution in humans. Chem. Immunol. Allergy. 2003, v. 82, р. 33-43.
  3. Moingeon P., Batard T., Fadel R. et al. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy. 2006, v. 61, № 2, p.151-165.
  4. Shanahan F. Nutrient Tasting and Signaling Mechanisms in the Gut. Mechanisms of immunologic sensation of intestinal contents. F. Am. J. Physiol. 2000, v. 278, p. 191-196.
  5. Taylor A., Verhagen J., Akdis C.A., Akdis M. T regulatory cells in allergy and health: a question of allergen specificity and balance. Int. Arch. Allergy Immunol. 2004, v. 135, No. 1, р. 73-82.
  6. Takahashi T, Kuniyasu Y., Toda M. et al. Immunologic self tolerance maintained by CD25+CD4+naturally anergic and suppressive T-cells: induction of autoimmune disease by breaking their aneigic/suppressivc state. Int. Immunol. 1998, v. 10, p. 1969-1980.
  7. Brunkow M., Jeffery E., Hjerrild К. et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the falal lymhoproliferative disorder of the scurfy mouse. Nat. Genet. 2001, v. 27, p. 68-73.
  8. Гущин И.С. Аллергическое воспаление и его фармакологический контроль. М., «Фармарус Принт». 1998, 251 с.
  9. Criado Molina A., Guerra Pasadas F., Daza Munoz J.C. et al. Immunotherapy with an oral Alternaria extract in childhood asthma. Clinical safety and efficacy and effects on in vivo and in vitro parameters. Allergol. Immunopathol. 2002, v. 30, No. 6, p. 319-330.
  10. Buchanan A.D., Green T.D., Jones S.M. et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy. J. Allergy Clin. Immunol. 2008, v. 121, No. 1, p. 270-271.
  11. Patriarca G., Nucera E., Roncallo C. et al. Oral desensitizing treatment in food allergy: clinical and immunological results. Aliment. Pharmacol. Ther. 2003, v. 17, № 3, p. 459-465.
  12. Meglio P., Bartone E., Plantamura M. et al. A protocol for oral desensitization in children with IgE-mediated cows milk allergy. Allergy. 2004, v. 59, p. 980-987.
  13. Staden U., Rolinck-Werninghaus C., Brewe F. et al. Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction. Allergy. 2007, v. 62, № 11, p. 1261-1269.
  14. TePas E.C., Hoyte E.G., McIntire J.J., Umetsu D.T. Clinical efficacy of microencapsulated timothy grass p ollen extract in grass-allergic individuals. Ann. Allergy Asthma. Immunol. 2004, v. 92, No. 1, p. 1-2.
  15. Петрова С.Ю. Методы комплексного лечения атопичес-кого дерматита, вызванного клещевыми аллергенами, с использованием иммунотерапии. Автореферат диссертации канд. мед. наук. M., 2001, 24 с.
  16. Выхристенко Л.Р., Новиков П.Д., Янченко В.В. Связь клинической эффективности различных способов специфической аллерговакцинации больных бронхиальной астмой с уровнем антител к аллергену домашней пыли. Иммунопатол. аллергол. инфектол. 2001, № 1, с. 69-78.
  17. Suko M., Mori A., Ito K., Okudaira H. Oral immunotherapy may induce T-cell anergy. Int. Arch. Allergy Immunol. 1995, v. 107, suppl. 1-3, p. 278-281.
  18. Генералов И.И., Новиков Д.К. Изменение амидазной активности препаратов IgG у больных бронхиальной астмой до и после специфической иммунотерапии. Иммунопатол. аллергол. инфектол. 1999, № 1, с. 57-60.
  19. Rask C., Holmgren J., Fredriksson M. et al. Prolonged oral treatment with low doses of allergen conjugated to cholera toxin B subunit suppresses immunoglobulin E antibody responses in sensitized mice. Clin. Exp. Allergy. 2000, v. 30, No. 7, p. 1024-1032.
  20. Gozalo F., Marthin S., Rico P. et al. Clinical efficacy and tolerance of two year Lolium perenne sublingual immunotherapy. Allergol. Immunopathol. 1997, v. 25, No. 5, p. 219-227.
  21. Marcucci F., Sensi L., Frati F. et al. Effects on inflammation parameters of a double-blind, placebo controlled one-year course of SLIT in children monosensitized to mites. Allergy. 2003, v. 58, № 7, p. 657-662.
  22. Jutel M., Akdis M., Budak F. et al. IL-10 and TGF-beta cooperate in the regulatory T-cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur. J. Immunol. 2003, v. 33, p. 1205-1214.
  23. Ciprandy G., Fenoglio D.I., Cirillo I. et al. Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann. Allergy Asthma Immunol. 2005, v. 95, p. 38-44.
  24. Giovane A.L., Bardare M., Passalacqua G. et al. A three year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in pediatric patients. Clin. Exp. Allergy. 1994, v. 24, p. 53-59.
  25. Pacor M.L., Biasi D., Carletto A., Lunardi C. Effectiveness of oral immunotherapy in bronchial asthma caused by Dermatophagoides pternyssinus. Recenti Prog. Med. 1995, v. 86, No. 12, p. 489-491.
  26. Openheimer J., Areson J.G., Nelson H.S. Safety and efficacy of oral immunotherapy with standartized cat extract. J. Allergy Clin. Immunol. 1994, v. 93, p. 61-67.
  27. Пампура А.Н., Смирнова М.О. Возможности пероральной аллерген-специфической иммунотерапии в лечении пищевой аллергии у детей. Рос. Аллергол. Журн. 2005, № 9, с. 29-35.
  28. Taudorf E., Laursen L.C., Lanner A. et al. Oral immuno-therapy in birch pollen hayfever. J. Allergy Clin. Immunol. 1987, v. 80, p. 153-161.
  29. Urbanek R., Burgelin K.H., Kahle S. et al. Oral immuno-therapy with grass pollen in enterosoluble capsules. A prospective study of the cliniсal and immunological response. Eur. J. Pediatr. 1990, v. 149, p. 545-550.
  30. Cooper P.J., Darbyshire J., Nunn A.J., Warner J.O. A controlled trial of oral hyposensitization in pollen asthma and rhinitis in children. Clin. Allergy. 1984, v. 14, p. 541-550.
  31. Mosbech H., Dreborg S., Madsen F. et al. High dose grass pollen tablets used for hyposensitization in hay fever patients. A one-year double blind placebo-controlled study. Allergy. 1987, v. 42, p. 451-455.
  32. Смолкин Ю.С., Ветров В.П., Страхова М.С. Иммунотерапия при атопических заболеваниях у детей. Рос. мед. журн. 1998, № 6, c. 50-54.
  33. Sharif S., Wheeler A.W., O'Hagan D.T. Biodegradable mi-croparticles as a delivery system for the allergens of Derma-tophagoides pteronyssinus (house dust mite). Preparation and characterisation of microparticles. Int. J. Pharm. 1995, v. 119, p. 239-243.
  34. Joint Task Force on Practice Parameters. Allergen immunotherapy: American Academy of Allergy, Asthma and Immunology American College of Allergy, Asthma and Immunology. Ann. Allergy Asthma Immunol. 2003, v. 90, suppl 1, p. 1-40.
  35. Cox S., Linnemann L., Nolte H. et al. Sublingual immuno-therapy: a comprehensive review. Allergy Clin. Immunol. 2006, v. 117, No. 5, p. 1021-1035.
  36. Sato M.N., Carvalho A.F., Silva A.O. et al. Low dose of orally administered antigen down-regulates the T helper type 2-response in a murine model of dust mite hypersensitivity. Immunology. 1998, v. 3, p. 338-344.
  37. Новиков Д.К., Выхристенко Л.Р. Современные методы специфической иммунотерапии аллергических заболеваний. Аллергология и иммунология. 2003, т. 4, № 2, с. 37-50.
  38. Хаитов М.Р. Рекомбинантные аллергены. Стратегия создания аллерговакцин нового поколения. Рос. Аллергол. Журн. 2004, № 1, с. 73-76.
  39. Федосеева В.Н. Разработка аллерговакцин на основе генно-инженерных технологий. Рос. Аллергол. Журн. 2009, № 1, с. 10-17.
  40. Chapman M.D., Smith A.M., Vailes L.D., Pomes A. Recombinant Allergens for Immunotherapy. Allergy and Asthma Proceeding. 2002, v. 23, No. 1, p. 5-8.
  41. Bernstein D.I., Wanner M., Borish L., Liss G.M. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J. Allergy Clin. Immunol. 2004, v. 113, p. 1129-1136.
  42. Matsunaga Y., Wakatsuki Y., Tabata Y. et al. Oral immunization with size-purified microsphere beads as a vehicle selectively induces systemic tolerance and sensitization. Vaccine. 2000, v. 19, p. 579-588.
  43. Fattal E., Pecquet S., Couvreur P., Andremont A. Biodegradable microparticles for the mucosal delivery of antibacterial and dietary antigens. Int. J. Pharm. 2002, v. 242, p. 15-24.
  44. Roth-Walter F., Scholl I., Untersmayr E. et al. Functio-nalisation of allergen-loaded microspheres with wheat germ agglutinin for targeting enterocytes. Biochem. Biophys. Res. Commun. 2004, v. 315, p. 281-287.
  45. Litwin A., Flanagan M., Entis G. et al. Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: 45. a double-blind study. Allergy Clin. Immunol. 1997, v. 100, No. 1, p. 30-38.
  46. Chew J.L., Wolfowicz C.B., Mao H.Q. et al. Chitosan nanoparticles containing plasmid DNA encoding house dost mite allergen, Der p 1 for oral vaccination in mice. Vaccine. 2003, v. 21, p. 2720-2729.
  47. Scholl I., Boltz-Nitulescu G., Jensen-Jarolim E. Review of novel particulale antigen delivery systems with special focus on treatment of type I allergy. J. Control Release. 2005, v. 104, p. 1-27.
  48. Perez O., Bracho G., Lastre M. et al. Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern. Immunol. Cell. Biol. 2005, v. 83, No. 2, p. 200.
  49. Allam J.P., Peng W.M., Appel T. et al. Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J. Allergy Clin. Immunol. 2008, v. 121, No. 2, p. 368-374.
  50. Takaiwa F. A rice-based edible vaccine expressing multiple T-cell epitopes to induce oral tolerance and inhibit allergy. Immunol. Allergy Clin. North. Am. 2007, v. 27, No. 1, p. 129-139.
  51. Hiroi T., Takaiwa F. Peptide immunotherapy for allergic diseases using a rice-based edible vaccine. Curr. Opin. Allergy Clin. Immunol. 2006, v. 6, No. 6, р. 455-460.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2009



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies